Shares of Clover Health Corp (CLOV) tumbled 14.77% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results. The healthcare technology company reported mixed results, with revenue growth outpacing expectations but earnings falling short of analyst estimates.

Clover Health posted a quarterly loss of $(0.05) per share, missing the analyst consensus estimate of $(0.03) by 66.67%. This represents a significant decline from the $(0.02) per share loss reported in the same period last year. On a more positive note, the company's quarterly sales reached $496.65 million, surpassing the analyst consensus estimate of $471.091 million by 5.43%. This marks a substantial 50.05% increase compared to sales of $330.986 million in the year-ago quarter.

Despite the strong revenue growth, investors seemed to focus on the company's profitability metrics. Clover Health reported a GAAP net loss of $24 million for the quarter. Additionally, Adjusted EBITDA came in at $2 million, falling well below the IBES estimate of $11.4 million. The company highlighted its Medicare Advantage membership growth, which reached 109,226, up 35% from the prior year. However, the market's negative reaction suggests concerns about Clover Health's path to profitability and its ability to control costs in a rapidly growing business. The company's outlook for 2026, projecting Adjusted Net income between $15.0 million and $30.0 million, may not have been sufficient to allay investor concerns in the short term.